Title: Risk heterogeneity in compartmental HIV transmission models of ART as prevention in Sub-Saharan Africa: A scoping review

Short Title: Heterogeneity in transmission models

Authors: Jesse KNIGHT^{1,a,*}, Rupert KAUL^{2,b}, and Sharmistha MISHRA^{1,3,4,5,c}

¹Institute of Medical Science, University of Toronto, Toronto, Canada

²Department of Medicine, University of Toronto, Toronto, Canada

³MAP Centre for Urban Health Solutions, Unity Health Toronto, Toronto, Canada

⁴Division of Infectious Disease, Department of Medicine, University of Toronto, Toronto, Canada

⁵Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada

^aORCID: 0000-0002-0455-5455

^bORCID: 0000-0002-1586-4093

^cORCID: 0000-0001-8492-5470

*Corresponding Author: jesse.knight@mail.utoronto.ca

Date: March 27, 2021

RISK HETEROGENEITY IN COMPARTMENTAL HIV TRANSMISSION MODELS OF ART AS PREVENTION IN SUB-SAHARAN AFRICA: A SCOPING REVIEW

Abstract

Objective. Transmission models provide complementary evidence to clinical trials about the potential population-level incidence reduction attributable to ART (ART prevention impact). Different modelling assumptions about risk heterogeneity may influence projected ART prevention impacts. We sought to review representations of risk heterogeneity in compartmental HIV transmission models applied to project ART prevention impacts in Sub-Saharan Africa. **Design.** Scoping review to identify common modelling assumptions and applications. **Methods.** We systematically reviewed studies published before January 2020 that used non-linear compartmental models of sexual HIV transmission to simulate ART prevention impacts in Sub-Saharan Africa. We summarized data on model structure/assumptions (factors) related to risk and intervention heterogeneity, and explored crude associations of ART prevention impact with modelled factors. **Results.** Of 1384 search hits, 94 studies were included, which primarily modelled medium/high prevalence epidemics in East/Southern Africa. 64 studies considered sexual activity stratification and 39 modelled at least one key population. 21 studies modelled faster/slower ART cascade transitions (HIV diagnosis, ART initiation, or cessation) by risk group, including 8 with faster and 4 with slower cascade transitions among key populations versus the wider population. Models without activity stratification predicted the largest ART prevention impacts, followed by models with key populations that had faster cascade transitions versus the wider population. **Conclusions.** Among compartmental transmission models applied to project ART prevention impacts, representations of risk heterogeneity and projected impacts varied considerably, where models with less heterogeneity tended to predict larger impacts. The potential influence of modelling assumptions about risk and intervention heterogeneity should be further explored.

Keywords: HIV, mathematical model, transmission, risk heterogeneity, key populations, antiretroviral therapy, universal test and treat

1 Introduction

As of 2019, two thirds (25.7 million) of all people living with HIV globally were in Sub-Saharan Africa (SSA), where an estimated one million new HIV infections were acquired in 2019 [1]. Data suggest that key populations, including individuals engaged in sex work and men who have sex with men, experience disproportionate risks of HIV acquisition and onward transmission in SSA [2, 3, 4, 5]. HIV treatment to reduce onward transmission remains a key element of combination HIV prevention [6]. Effective HIV treatment with antiretroviral therapy (ART) leads to viral load suppression and has been shown to prevent HIV transmission between sex partners [7, 8, 9].

Following empirical evidence of partnership-level efficacy of ART in preventing HIV [7, 8, 9], and model-based evidence of “treatment as prevention” [10, 11, 12], several large-scale community-based trials of universal test-and-treat (UTT) were recently completed [13, 14, 15]. These trials found that over 2-to-4 years, cumulative incidence under UTT did not significantly differ from cumulative incidence under ART according to national guidelines [14, 15, 13]. Thus the population-level reductions in incidence anticipated from transmission modelling were not observed in these trials [16, 17].

One theme in the proposed explanations for limited population-level ART prevention effectiveness was heterogeneity in intervention coverage and its intersection with heterogeneity in transmission risks [18, 16]. While viral suppression improved under UTT in all three trials, 21–54% of study participants remained unsuppressed [13, 14, 15]. It has been suggested that populations experiencing barriers to viral suppression under UTT may be at highest risk for onward transmission, including key populations like sex workers, men who have sex with men, and adolescent girls and young women [19, 20, 21]. While widespread UTT scale-up may fill some coverage gaps, equitable access to ART for marginalized populations remains an open challenge.

Given the upstream and complementary role of transmission modelling in estimating the prevention impacts of ART [11, 22], we sought to examine and appraise representations of risk heterogeneity in mathematical models used to assess the prevention impacts of ART in SSA. We conducted a scoping review with the following objectives. Among non-linear compartmental models of sexual HIV transmission that have been used to simulate the prevention impacts of ART in SSA:

1. In which epidemic contexts (geographies, populations, epidemic phases) have these models been applied?

2. How was the model structured to represent key factors of risk heterogeneity?
3. What are the potential influences of representations of risk heterogeneity on the projected prevention benefits of ART for all?

2 Methods

We conducted a scoping review according to the PRISMA extension for scoping reviews (Appendix D). First, we developed a conceptual framework to organize assumptions and representations of risk heterogeneity in compartmental HIV transmission models. Then, we designed and implemented the search strategy, and extracted data relevant to the framework to address our objectives.

2.1 Conceptual Framework for Risk Heterogeneity

We conceptualized “factors of risk heterogeneity”, meaning epidemiological stratifications and phenomena which may/not be included in transmission models. Such factors could include if/how populations, rates, and probabilities are stratified along various dimensions. We defined the following 4 domains in which different factors of risk heterogeneity might influence the transmission impact of ART.

- **Biological Effects:** differential transmission risk within HIV disease course that may coincide with differential ART coverage [23]
- **Behaviour Change Effects:** differential transmission risk due to behavioural changes related to engagement in the ART cascade [24, 25]
- **Network Effects:** differential transmission risk within sub-populations that increases the challenge of epidemic control through core group dynamics [26, 27, 28]
- **Coverage Effects:** differential transmission risk within sub-populations who experience barriers to ART care and achieving viral suppression, such as youth and key populations [29, 30, 19, 21]

We then compiled a list of key factors of risk heterogeneity, and their possible mechanisms of influence on ART prevention impact (Table 1).

Table 1: Factors of heterogeneity in HIV transmission and their possible mechanisms of influence on the prevention impact of ART interventions

Factor	MP ^a	Definition	Possible mechanism(s) of influence on ART prevention impact
Acute Infection	β_i	Increased infectiousness immediately following infection [31, 32]	Biological: transmissions during acute infection are unlikely to be prevented by ART
Late-Stage Infection	β_i	Increased infectiousness during late-stage infection [31, 32]	Biological: transmissions during late-stage are more likely to be prevented by ART
Drug Resistance	β_i	Transmitted factor that requires regimen switch to achieve viral suppression [33]	Biological: transmissions during longer delay to achieving viral suppression will not be prevented by ART
HIV Morbidity	$c; \eta$	Reduced sexual activity during late-stage disease [34, 35]	Behaviour Change: reduced morbidity via ART could increase HIV prevalence among the sexually active population
HIV Counselling	$c; \eta; \kappa$	Reduced sexual activity and/or increased condom use after HIV diagnosis [25]	Behaviour Change: increased HIV testing with ART scale up can contribute to prevention even before viral suppression is achieved
Activity Groups	$c; \kappa$	Any stratification by rate of partnership formation [36]	Network: higher transmission risk among higher activity
Age Groups	$c; \kappa$	Any stratification by age	Network & Coverage: higher transmission risk and barriers to viral suppression among youth [37, 24]
Key Populations	$c; \kappa$	Any epidemiologically defined higher risk groups [38]	Network & Coverage: higher transmission risk and barriers to viral suppression among key populations [19]
Group Turnover	ϕ	Individuals move between activity groups and/or key populations reflecting sexual lifecourse [27]	Network & Coverage: counteract effect of stratification due to shorter periods in higher risk [39]; viral suppression may be achieved only after periods of higher risk
Assortative Mixing	m	Any degree of assortative mixing (like-with-like) by age, activity, and/or key populations	Network: assortative sexual networks compound effect of stratification [36]
Partnership Types	$\eta; \kappa$	Different partnership types are simulated, with different numbers of sex acts and/or condom usage [40]	Network: longer duration and lower condom use among main versus casual/sex work partnerships counteracts effect of stratification
ART Cascade Gaps	$\tau; \alpha$	Slower ART cascade transitions among higher activity groups or key populations [19, 24]	Coverage: ART prevention benefits may be allocated differentially among risk groups

^a MP: Model Parameters — β_i, β_s : transmission probability per act (infectiousness, susceptibility); η : number of sex acts of each type per partnership; κ : proportion of sex acts unprotected by a condom; c : partnership formation rate; m : mixing matrix (probability of partnership formation); μ : mortality rate; v : entry rate; ϕ : internal turnover between activity groups; τ : testing rate; α : ART initiation rate (and retention-related factors).

2.2 Search

We searched MEDLINE and EMBASE via Ovid using search terms related to Sub-Saharan Africa (SSA), HIV, and transmission modelling (Appendix A.1). Search results were imported into Covidence [41] for screening. Duplicate studies were removed automatically by Ovid and by Covidence; four additional duplicates with subtly different titles were later identified and removed manually. Potentially relevant studies were identified by title and abstract screening, followed by full-text screening using the inclusion/exclusion criteria below. One reviewer (JK) conducted the search, screening, and data extraction.

2.2.1 Inclusion/Exclusion Criteria

We included peer-reviewed, primarily modelling studies that used non-linear models of sexual HIV transmission to project the prevention impacts of ART in any setting within SSA. See Appendix A.2 for complete inclusion/exclusion criteria. We only included studies published in English anytime before Jan 1, 2020. We excluded conference publications and those without primary modelling results and description of the methods, such as commentaries and reviews. If a model's details were provided in another peer-reviewed publication, we extracted data from both publications as required.

The following criteria were used for inclusion of studies: 1) Used a non-linear compartmental model of sexual HIV transmission at the population level. We defined a *non-linear model* as one where future projected infections are a function of previously projected infections [42], and a *compartmental model* as one where system variables represent the numbers of individuals in each state, rather than unique individuals [42]. Thus, statistical models, models without dynamic transmission, and individual-based models were excluded. 2) The model was parameterized/calibrated to reflect at least one setting within SSA (see Appendix B.1 for countries). 3) The study simulated at least one scenario with increasing ART coverage, possibly alongside other interventions. The included studies formed Dataset A, used to complete objectives 1 and 2.

A subset of Dataset A formed Dataset B, used to complete objective 3. Studies in Dataset B specifically examined scale-up of ART coverage alone (versus combination intervention) for the whole population (versus ART prioritized to subgroups), and reported HIV incidence reduction or cumulative HIV infections averted over time relative to a base-case scenario reflecting status quo.

2.3 Data Extraction

Data extraction used the full text and all available supplementary material. Data were extracted per-study for objectives 1 and 2, and per-scenario for objective 3. Detailed variables definitions are given in Appendix B.

2.3.1 Epidemic Context

For objective 1, we extracted data on geography, epidemic phase, and key populations explicitly considered in the model. We categorized studies by country and SSA region, and scale of the simulated population (city, sub-national, national, regional). We classified epidemic size at time of ART intervention using overall HIV prevalence (low: <1%, medium: 1–10%, high: >10%), and epidemic phase using overall HIV incidence trend (increasing, increasing-but-stabilizing, stable/equilibrium, decreasing-but-stabilizing, and decreasing).

We extracted whether any of the following key populations were modelled: female sex workers (FSW); male clients of FSW (Clients); men who have sex with men (MSM); and people who inject drugs (PWID). FSW were defined as any female activity group meeting 3 criteria: <5% of the female population; <1/3 the client population size; and having >50× the partners per year of the lowest sexually active female activity group [43, 40]. Clients were defined as any male activity group described as clients of FSW, and being >3× the FSW population size. We also extracted whether any groups in the model were described as MSM or PWID.

2.3.2 Factors of Risk Heterogeneity

For objective 2, we examined if/how the factors of risk heterogeneity outlined in Table 1 were simulated in each study. We examined the number of *risk groups* defined by sex and/or sexual activity, and any *turnover* of individuals between activity groups and/or key populations.

We classified how *partnership types* were defined: generic (all partnerships equal); based only on the activity groups involved; or overlapping, such that different partnership types could be formed between the same two activity groups. We extracted whether partnerships considered different numbers of sex acts (sex frequency and partnership duration) and condom use, and whether models simulated any degree of assortative *mixing* by activity groups (preference for like-with-like) versus proportionate (random) mixing. The number of *age groups* was extracted, and whether *mixing* by age groups was proportionate, strictly assortative, or assortative

with age differences. We extracted whether age conferred any transmission risk beyond mixing, such as different partnership formation rates.

Finally, we extracted whether rates of HIV diagnosis, ART initiation, and/or ART discontinuation differed across risk strata (sex, activity, key populations, and/or age), and if so, how they differed.

2.3.3 ART Prevention Impact

For objective 3, we extracted the following data for each intervention scenario within Dataset B: the years that ART scale-up started (t_o) and stopped (t_f); the final overall ART coverage achieved and/or the final ART initiation rate (per person-year among PLHIV not yet in care); the criteria for ART initiation (e.g. CD4 count); and the relative reduction in transmission probability on ART. Then, we extracted the relative reduction in incidence and/or proportion of infections averted relative to the base-case scenario for available time horizons relative to t_o .

Finally, for each factor of heterogeneity, we compared projected ART impacts (incidence reduction/infections averted) across different factor levels (whether or not, and how the factor was modelled). We plotted the impacts versus time since t_o , stratified by factor levels, and explored whether projected impacts were the same under all factor levels, testing for significant differences using a Kruskal-Wallis test.

3 Results

The search yielded 1384 publications, of which 94 studies were included (Figure 1). These studies (Dataset A) applied non-linear compartmental modelling to simulate ART scale-up in SSA, of which 40 reported infections averted/incidence reduction due to population-wide ART scale-up without combination intervention, relative to a base-case reflecting status quo (Dataset B). Appendix A.3 lists the included papers, and Appendix C provides additional results.

3.1 Epidemic Context

Table 2 summarizes key features of contexts within SSA where the prevention impacts of ART have been modelled. Most (61) of the 94 studies modelled HIV transmission at the national level; studies also explored regional (1), sub-national (16), and city-level (16) epidemic scales. South Africa was the most common

Figure 1: PRISMA flowchart of study identification

Figure 2: Map showing number of studies (of 94 total) applying HIV transmission modelling in each country vs the number of people living with HIV (PLHIV, millions)

country simulated (52 studies), and Figure 2 illustrates the number of studies by country. East Africa was the most represented SSA region, being simulated in 77 studies, followed by Southern (73), West (28), and Central Africa (13).

ART prevention impacts were most often modelled in high-prevalence (>10%) epidemics (41 studies) and medium-prevalence (1–10%) epidemics, 23). No studies reported overall HIV prevalence of <1% at time of intervention, although for 30 studies, HIV prevalence was either not reported or varied across simulated contexts/scenarios. The median [min, (IQR), max] year of intervention was 2014 [1990, (2010, 2015), 2040]; at which time HIV prevalence (%) was 15 [2, (6, 19), 32]; and incidence (per 1000 person-years) was 14 [1, (9, 20), 50]. Most reported incidence trends were decreasing or stable (45 of 48 reporting).

Table 2: Summary of epidemic contexts within Sub-Saharan Africa where the prevention impacts of ART have been modelled

Study Characteristic		Studies
Geographic scale	Regional	1
	National	61
	Sub-national	16
	City	16
Modelled countries ^a	South Africa	52
	Kenya	22
	Zambia	10
	Other	30
HIV prevalence	Low (<1%)	0
	Mid (1-10%)	23
	High (>10%)	41
	Unclear/Varies	30
Incidence trend at scenario divergence	Decreasing	10
	Dec-to-stable	24
	Stable	11
	Inc-to-stable	1
	Increasing	2
	Unclear/Varies	46
Key populations included	FSW ^b	39
	Clients ^c	31
	MSM	28
	PWID	11

Total studies: 94. FSW: female sex workers; Clients: clients of sex workers; MSM: men who have sex with men; PWID: people who inject drugs. ^a Does not sum to 94 as some studies modelled multiple countries. ^b Groups described as FSW, not considering the epidemiological definitions given in Appendix B.2.1. ^c Likewise for clients, and excluding studies where clients were modelled as a proportion of another risk group.

3.1.1 Key Populations

Groups representing FSW were described in 39 studies. Among these (of studies where it was possible to evaluate): 21 (of 25) were $<5\%$ of the female population; 14 (of 24) were $<1/3$ the size of the client population; and 15 (of 22) had $>50\times$ partners per year versus the lowest sexually active female activity group. Clients of FSW were modelled as a unique group in 31 studies, among which 8 (of 17 reporting) were $>3\times$ the size of the FSW population. In another 8 studies, clients were defined as a proportion of another group, among which 6 (of 7) were $>3\times$ the FSW population size. Activity groups representing men who have sex with men (MSM) were noted in 28 studies; and people who inject drugs (PWID) in 11.

3.2 Heterogeneity Factors

3.2.1 Biological Effects

The median [min, (IQR), max] number of states used to represent HIV disease (ignoring treatment-related stratifications) was 5 [1, (3, 6), 25], and 2 studies represented HIV along a continuous dimension using partial differential equations. States of increased infectiousness associated with acute infection and late-stage disease were simulated in 68 and 74 studies, respectively.

The relative risk of HIV transmission on ART was 0.08 [0, (0.04, 0.13), 0.3], representing an average “on-treatment” state in 78 studies, versus a “virally suppressed” state in 15. Treatment failure due to drug resistance was simulated in 24 studies, including: 23 where individuals experiencing treatment failure were tracked separately from ART-naive; and 1 where such individuals transitioned back to a generic “off-treatment” state. Another 6 studies included a similar transition that was not identified as treatment failure versus ART cessation. Transmissible drug resistance was simulated in 9 studies.

3.2.2 Behavioural Effects

Reduced sexual activity during late-stage HIV was simulated in 25 studies, including at least one state with: complete cessation of sexual activity (14); reduced rate/number of partnerships (9); and/or reduced rate/number of sex acts per partnership (6).

Separate health states representing diagnosed HIV before treatment, and on-treatment before viral suppression were simulated in 30 and 17 studies, respectively. 22 studies modelled behaviour changes following

awareness of HIV+ status, including: increased condom use (12); fewer partners per year (4); fewer sex acts per partnership (3); serosorting (1); and/or a generic reduction in transmission probability (8).

ART cessation was simulated in 35 studies, including: 16 where individuals no longer on ART were tracked separately from ART-naïve; and 19 where such individuals transitioned back to a generic “off-treatment” state. Another 6 studies included a similar transition that was not identified as treatment failure versus ART cessation.

3.2.3 Network Effects

Populations were stratified by activity (different rates and/or types of partnerships formed) in 59 studies, and by sex in 64. The number of groups defined by sex and/or activity was 6 [1, (2, 9), 19]; and by activity alone (maximum number of groups among: heterosexual women, heterosexual men, MSM, or overall if sex was not considered) was 3 [1, (1, 3), 18]. The highest activity groups for females and males (possibly including FSW/clients) comprised 2 [< 1 , (2, 4), 23] and 9 [< 1 , (2, 14), 35] % of female and male populations, respectively.

Turnover between activity groups and/or key populations was considered in 28 studies, of which 9 considered turnover of only one specific high-activity group or key population. Another 7 studies simulated movement only from lower to higher activity groups to re-balance group sizes against disproportionate HIV mortality.

Among 59 studies with activity groups, sexual mixing was assumed to be assortative in 57 and proportionate in 2. Partnerships had equal probability of transmission in 39 studies, including all studies without activity groups. Partnerships were defined by the activity groups involved in 44 studies, among which transmission was usually lower in high-with-high activity partnerships than in low-with-low, due to fewer sex acts (31) and/or increased condom use (23). Transmission risk in high-with-low activity partnerships was defined by: the susceptible partner (9); the lower activity partner (11); the higher activity partner (3); or both partners' activity groups (15); yielding indeterminate, higher, lower, or intermediate per-partnership transmission risk, respectively. Partnerships were defined based on overlapping types, such that different partnership types could be formed between the same two activity groups in 11 studies. All models with overlapping partnership types defined differential total sex acts and condom use between types.

Age groups were simulated in 32 studies, among which, the number of age groups was 10 [2, (4, 34), 91], and 2 studies simulated age along a continuous dimension. Sexual mixing between age groups was assumed to be assortative either with (23) or without (3) average age differences between men and women; or proportionate (6). Differential risk behaviour by age was modelled in 29 studies.

3.2.4 Coverage Effects

Differential transition rates along the ART cascade were considered in 21 studies, including differences between sexes in 15; age groups in 7; and key populations in 12. Another 2 studies did not simulate differential cascade transitions, but specifically justified the decision using context-specific data. Differences between sexes included rates of HIV diagnosis (11); ART initiation (6); and ART cessation (1), with cascade engagement higher among women, in most cases attributed to antenatal services. Differences between age groups also affected rates of diagnosis (6); ART initiation (1); but not ART cessation (0). Among key populations, *lower* rates of diagnosis, ART initiation, and retention were simulated in 0, 2, and 4 studies respectively, while *higher* rates were simulated in 8, 2, and 1.

3.3 ART Prevention Impact

Dataset B comprised 40 studies, including 125 scenarios of ART scale-up. Relative incidence reduction with ART scale-up as compared to a scenario without ART scale-up was reported in 23 studies (61 scenarios); the proportion of cumulative infections averted due to ART scale-up was reported in 24 (75); and 7 (11) reported both. Some scenarios reported these outcomes on multiple time horizons.

Figure 3 summarizes each outcome versus time since ART scale-up, stratified by a composite index of modelled risk heterogeneity. Ecological-level analysis across scenarios by degree of risk heterogeneity identified differences in proportions of infections averted, but not in relative incidence reduction (Table C.1). The largest proportions of infections averted were reported from scenarios without risk heterogeneity (median [IQR]% = 29 [18, 47]), followed by scenarios with key populations prioritized for ART (21 [11, 41]). The smallest impact was observed in scenarios with key populations who were not prioritized for ART (10 [3, 21]) and in models with risk heterogeneity but without key populations (6 [3, 22]). Only 11 scenarios from 7 studies provided both outcomes [44, 45, 46, 47, 48, 49, 50]; among which the pattern of incidence reduction

Figure 3: Projected ART prevention benefits, stratified by factors of risk heterogeneity: whether models considered differences in sexual activity, key populations, and ART cascade prioritized to key populations

The number of studies (scenarios) reporting incidence reduction, cumulative infections averted, both, or either was: 23 (61), 24 (75), 7 (11), and 40 (125), respectively (Dataset B). If any study included multiple scenarios of ART scale-up, then each scenario was included as a separate data point, but the size of each data point was reduced in proportion to the number of scenarios in the study. Some scenarios have multiple data points if multiple time horizons were reported. A small random offset was added to all data points to reduce overlap. KP: key populations; priority: cascade transitions were faster for at least one step among KP vs overall; same: cascade transitions were assumed the same speed in KP as overall; no scenarios in Dataset B considered lower cascade among KP.

versus modelled heterogeneity was similar to the pattern of infections averted versus modelled heterogeneity (Figure C.40).

Appendix C.2 and Table C.1 summarizes ART prevention impacts (relative incidence reduction/proportion of infections averted), stratified by other factors of risk heterogeneity, epidemic contexts, and intervention conditions. ART prevention impacts were larger with longer time horizon, greater ART eligibility, and higher ART coverage.

4 Discussion

Via scoping review, we found that representations of risk heterogeneity varied widely across transmission modelling studies of ART intervention in SSA, with stratification by sexual activity and key populations

considered in approximately 2/3 and 2/5 of models, respectively. We also found that the projected proportions of infections averted due to ART scale-up were larger under assumptions of homogeneous risk or prioritized ART to key populations, as compared to heterogeneous risk or without prioritized ART to key populations. Three notable themes emerged from our review.

First, modelling studies have an opportunity to keep pace with growing epidemiological data on risk heterogeneity. For example, 41% of the modelling studies reviewed included at least one key population, such as FSW and or MSM. Key populations continue to experience disproportionate risk of HIV, even in high-prevalence epidemics [1], and models examining the unmet needs of key populations suggest that these unmet needs play an important role in overall epidemic dynamics [51, 52]. Furthermore, we found that the number of modelled clients per female sex worker, and the relative rate of partnership formation among female sex workers versus other women did not always reflect the available data [27, 40]. Similarly, among studies with different partnership types, only 20% modelled main/spousal partnerships—with more sex acts/lower condom use—between two higher risk individuals, while 80% modelled only casual/commercial partnerships among higher risk individuals. However, data suggest female sex workers may form main/spousal partnerships with regular clients and boyfriends/spouses from higher risk groups [40]. Thus, future models can continue to include emerging data on these and other factors of heterogeneity, while nested model comparison studies can study how multiple factors might act together to influence projections of ART impact [28, 53].

Second, most models assumed equal ART cascade transition rates across subgroups, including diagnosis, ART initiation, and retention. Recent data suggest differential ART cascade by sex, age, and key populations [30, 54, 55, 21]. These differences may stem from the unique needs of population subgroups and is one reason why differentiated ART services are a core component of HIV programs [56, 57]. Moreover, barriers to ART may intersect with transmission risk, particularly among key populations, due to issues of stigma, discrimination, and criminalization [58, 16]. Thus, further opportunities exist to: incorporate differentiated cascade data, examine the intersections of intervention and risk heterogeneity, and to consider the impact of HIV services as they are delivered on the ground. Similar opportunities were noted regarding modelling of pre-exposure prophylaxis in SSA [59]. Finally, depending on the research question, the modelled treatment cascade may need expansion to include more cascade steps and states related to treatment failure/discontinuation.

Third, based on ecological analysis of scenarios, we found that modelling assumptions about risk and intervention heterogeneity may influence the projected proportion of infections averted by ART. We did not

find similar evidence for relative incidence reduction due to ART, but studies reporting both outcomes were largely distinct. Among studies reporting both, the overall pattern was consistent [44, 45, 46, 47, 48, 49, 50]. These findings highlight the limitations of ecological analysis to estimate the potential influence of modelling assumptions on projected ART prevention benefits, and motivate additional model comparison studies to better quantify this influence, such as [28, 53]. Our ecological analysis also suggested that the anticipated ART prevention impacts from homogeneous models may be achievable in the context of risk heterogeneity if testing and treatment resources are prioritized to higher risk groups.

Limitations of our scoping review include our examination of only a few key populations. In our conceptual framework for risk heterogeneity, we did not explicitly examine heterogeneity by type of sex act (i.e. anal sex) which is associated with higher probability of HIV transmission, nor structural risk factors like violence [60, 61]. The large number of differences between scenarios in the scoping review context also limited our ability to infer the influence of risk heterogeneity across scenarios.

In conclusion, representations of risk heterogeneity vary widely among models used to project the prevention impacts of ART in SSA. Such differences may partially explain the large variability in projected impacts. Opportunities exist to incorporate new and existing data on the intersections of risk and intervention heterogeneity. Moving forward, systematic model comparison studies are needed to estimate and understand the influence of various modelling assumptions on ART prevention impacts.

Conflicts of Interest

None declared.

Funding

The study was supported by the Natural Sciences and Engineering Research Council of Canada (NSERC CGS-D); Ontario Early Researcher Award No. ER17-13-043; and the Canadian Institutes of Health Research Foundation Grant (FN-13455).

Acknowledgements

We thank: Kristy Yiu (Unity Health Toronto) for research coordination support; Linwei Wang (Unity Health Toronto) for feedback on elements of the paper; and Kaitlin Fuller (University of Toronto) for her help designing the search strategy.

Contributions

JK and SM conceptualized and designed the study, and developed the search strategy. JK performed the search, extracted the data, conducted the analysis, and generated the results. JK and SM drafted the manuscript and appendix. All authors (JK, RK, and SM) reviewed the results and contributed to writing the manuscript.

References

- [1] UNAIDS. *AIDSinfo*. 2020.
- [2] Stefan Baral et al. “Burden of HIV among female sex workers in low-income and middle-income countries: A systematic review and meta-analysis”. In: *The Lancet Infectious Diseases* 12.7 (July 2012), pp. 538–549.
- [3] Chris Beyrer et al. “Global epidemiology of HIV infection in men who have sex with men”. In: *The Lancet* 380.9839 (July 2012), pp. 367–377.
- [4] Sharmistha Mishra et al. “Impact of High-Risk Sex and Focused Interventions in Heterosexual HIV Epidemics: A Systematic Review of Mathematical Models”. In: *PLoS ONE* 7.11 (Nov. 2012), e50691.
- [5] Marie Claude Boily et al. “What really is a concentrated HIV epidemic and what does it mean for West and Central Africa? Insights from mathematical modeling”. In: *Journal of Acquired Immune Deficiency Syndromes* 68 (Mar. 2015), S74–S82.
- [6] WHO. *Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection*. 2016.
- [7] Jens D Lundgren et al. “How achievable is immediate ART for all?” In: *The Lancet HIV* 2.9 (Aug. 2015), pp. 795–807.
- [8] “A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa”. In: *New England Journal of Medicine* 373.9 (Aug. 2015), pp. 808–822.
- [9] Myron S. Cohen et al. “Antiretroviral Therapy for the Prevention of HIV-1 Transmission”. In: *New England Journal of Medicine* 375.9 (Sept. 2016), pp. 830–839.
- [10] M. Granich et al. “Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model”. In: *The Lancet* 373.9657 (2009), pp. 48–57.
- [11] Jeffrey W. Eaton et al. “HIV treatment as prevention: Systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa”. In: *PLoS Medicine* 9.7 (July 2012), e1001245.

- [12] A. Cori et al. “HPTN 071 (PopART): A cluster-randomized trial of the population impact of an HIV combination prevention intervention including universal testing and treatment: Mathematical model”. In: *PLoS ONE* 9.1 (2014), e84511.
- [13] Collins C. Iwuji et al. “Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial”. In: *The Lancet HIV* 5.3 (Mar. 2018), e116–e125.
- [14] Diane V. Havlir et al. “HIV Testing and Treatment with the Use of a Community Health Approach in Rural Africa”. In: *New England Journal of Medicine* 381.3 (July 2019), pp. 219–229.
- [15] Richard J. Hayes et al. “Effect of universal testing and treatment on HIV incidence - HPTN 071 (popart)”. In: *New England Journal of Medicine* 381.3 (July 2019), pp. 207–218.
- [16] Stefan Baral et al. “The disconnect between individual-level and population-level HIV prevention benefits of antiretroviral treatment”. In: *The Lancet HIV* 6 (July 2019), e632–638.
- [17] Diane Havlir et al. “What do the Universal Test and Treat trials tell us about the path to HIV epidemic control?” In: *Journal of the International AIDS Society* 23.2 (Feb. 2020), e25455.
- [18] Salim S. Abdool Karim. “HIV-1 Epidemic Control — Insights from Test-and-Treat Trials”. In: *New England Journal of Medicine* 381.3 (July 2019), pp. 286–288.
- [19] Avi Joseph Hakim et al. “Gaps and opportunities: measuring the key population cascade through surveys and services to guide the HIV response”. In: *Journal of the International AIDS Society* 21 (July 2018), e25119.
- [20] Daniel Nyato et al. “Facilitators and barriers to linkage to HIV care and treatment among female sex workers in a community-based HIV prevention intervention in Tanzania: A qualitative study”. In: *PLoS ONE* 14.11 (Nov. 2019), e0219032.
- [21] Dylan Green et al. “Evidence of sociodemographic heterogeneity across the HIV treatment cascade and progress towards 90-90-90 in sub-Saharan Africa – a systematic review and meta-analysis”. In: *Journal of the International AIDS Society* 23.3 (Mar. 2020).
- [22] Wim Delva et al. “HIV treatment as prevention: Principles of good HIV epidemiology modelling for public health decision-making in all modes of prevention and evaluation”. In: *PLoS Medicine* 9.7 (July 2012), e1001239.
- [23] Christopher D. Pilcher et al. “Brief but efficient: Acute HIV infection and the sexual transmission of HIV”. In: *Journal of Infectious Diseases* 189.10 (May 2004), pp. 1785–1792.

- [24] Sanjeev Ramachandran et al. “How do HIV-negative individuals in sub-Saharan Africa change their sexual risk behaviour upon learning their serostatus? A systematic review”. In: *Sexually Transmitted Infections* 92.8 (Dec. 2016), pp. 571–578.
- [25] Ruchi Tiwari et al. “Sexual behaviour change following HIV testing services: a systematic review and meta-analysis”. In: *Journal of the International AIDS Society* 23.11 (Nov. 2020).
- [26] Marie Claude Boily and Benoît Mâsse. “Mathematical models of disease transmission: A precious tool for the study of sexually transmitted diseases”. In: *Canadian Journal of Public Health* 88.4 (1997), pp. 255–265.
- [27] C. Watts et al. “Remodelling core group theory: the role of sustaining populations in HIV transmission”. In: *Sexually Transmitted Infections* 86.Suppl 3 (Dec. 2010), pp. iii85–iii92.
- [28] Peter J Dodd, Geoff P Garnett, and Timothy B Hallett. “Examining the promise of HIV elimination by ‘test and treat’ in hyperendemic settings”. In: *AIDS* 24.5 (Mar. 2010), pp. 729–735.
- [29] Elisa Mountain et al. “Antiretroviral therapy uptake, attrition, adherence and outcomes among hiv-infected female sex workers: A systematic review and meta-analysis”. In: *PLoS ONE* 9.9 (Sept. 2014), e105645.
- [30] Kathryn E. Lancaster et al. “HIV care and treatment experiences among female sex workers living with HIV in sub-Saharan Africa: A systematic review”. In: *African Journal of AIDS Research* 15.4 (Dec. 2016), pp. 377–386.
- [31] T. Déirdre Hollingsworth, Roy M. Anderson, and Christophe Fraser. “HIV-1 transmission, by stage of infection”. In: *Journal of Infectious Diseases* 198.5 (Sept. 2008), pp. 687–693.
- [32] Marie Claude Boily et al. “Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies”. In: *The Lancet Infectious Diseases* 9.2 (Feb. 2009), pp. 118–129.
- [33] René de Waal et al. “HIV drug resistance in sub-Saharan Africa: public health questions and the potential role of real-world data and mathematical modelling.” In: *Journal of virus eradication* 4.Suppl 2 (Nov. 2018), pp. 55–58.
- [34] Landon Myer et al. “Impact of antiretroviral therapy on incidence of pregnancy among HIV-infected women in Sub-Saharan Africa: A cohort study”. In: *PLoS Medicine* 7.2 (Feb. 2010), e1000229.

- [35] Nuala McGrath, Linda Richter, and Marie Louise Newell. “Sexual risk after HIV diagnosis: A comparison of pre-ART individuals with CD4 > 500 cells/ μ l and ART-eligible individuals in a HIV treatment and care programme in rural KwaZulu-Natal, South Africa”. In: *Journal of the International AIDS Society* 16.1 (Jan. 2013), p. 18048.
- [36] R. M. Anderson et al. “The spread of HIV-1 in Africa: Sexual contact patterns and the predicted demographic impact of AIDS”. In: *Nature* 352.6336 (1991), pp. 581–589.
- [37] Isolde Birdthistle et al. “Recent levels and trends in HIV incidence rates among adolescent girls and young women in ten high-prevalence African countries: a systematic review and meta-analysis”. In: *The Lancet Global Health* 7.11 (Nov. 2019), e1521–e1540.
- [38] WHO. *Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations*. 2016.
- [39] Jesse Knight et al. “Contribution of high risk groups’ unmet needs may be underestimated in epidemic models without risk turnover: A mechanistic modelling analysis”. In: *Infectious Disease Modelling* 5 (Jan. 2020), pp. 549–562.
- [40] Fiona Scorgie et al. “Socio-demographic characteristics and behavioral risk factors of female sex workers in sub-Saharan Africa: A systematic review”. In: *AIDS and Behavior* 16.4 (May 2012), pp. 920–933.
- [41] Veritas Health Innovation. *Covidence systematic review software*. 2020.
- [42] Geoffrey P. Garnett et al. “Mathematical models in the evaluation of health programmes”. In: *The Lancet* 378.9790 (Aug. 2011), pp. 515–525.
- [43] J. Vandepitte et al. “Estimates of the number of female sex workers in different regions of the world”. In: *Sexually Transmitted Infections* 82.SUPPL. III (June 2006).
- [44] A. Salomon et al. “Integrating HIV prevention and treatment: From slogans to impact”. In: *PLoS Medicine* 2.1 (2005), pp. 0050–0056.
- [45] Ume L. Abbas, Roy M. Anderson, and John W. Mellors. “Potential impact of antiretroviral therapy on HIV-1 transmission and AIDS mortality in resource-limited settings.” In: *Journal of acquired immune deficiency syndromes (1999)* 41.5 (2006), pp. 632–41.
- [46] C. Pretorius et al. “Evaluating the Cost-Effectiveness of Pre-Exposure Prophylaxis (PrEP) and Its Impact on HIV-1 Transmission in South Africa”. In: *PLoS ONE* 5.11 (2010), e13646.
- [47] E. Nichols et al. “Cost-effectiveness of PrEP in HIV/AIDS control in Zambia: A stochastic league approach”. In: *Journal of Acquired Immune Deficiency Syndromes* 66.2 (2014), pp. 221–228.

- [48] T. Barnighausen, E. Bloom, and S. Humair. “Human resources for treating HIV/AIDS: Are the preventive effects of antiretroviral treatment a game changer?” In: *PLoS ONE* 11.10 (2016), e0163960.
- [49] M. Maheu-Giroux et al. “Population-level impact of an accelerated HIV response plan to reach the UNAIDS 90–90–90 target in Cote d’Ivoire: Insights from mathematical modeling”. In: *PLoS medicine* 14.6 (2017), e1002321.
- [50] G. Akudibillah, A. Pandey, and J. Medlock. “Optimal control for HIV treatment”. In: *Mathematical biosciences and engineering : MBE* 16.1 (2018), pp. 373–396.
- [51] Jack Stone et al. “Estimating the contribution of key populations towards HIV transmission in South Africa”. In: *Journal of the International AIDS Society* 24.1 (Dec. 2021), e25650.
- [52] G. Bekker et al. “Combination HIV prevention for female sex workers: What is the evidence?” In: *The Lancet* 385.9962 (2015), pp. 72–87.
- [53] Jan A.C. C. Hontelez et al. “Elimination of HIV in South Africa through Expanded Access to Antiretroviral Therapy: A Model Comparison Study”. In: *PLoS Medicine* 10.10 (Oct. 2013), e1001534.
- [54] Sheree Schwartz et al. “Engagement in the HIV care cascade and barriers to antiretroviral therapy uptake among female sex workers in Port Elizabeth, South Africa: Findings from a respondent-driven sampling study”. In: *Sexually Transmitted Infections* 93.4 (June 2017), pp. 290–296.
- [55] Huiting Ma et al. “Venue-Based HIV Testing at Sex Work Hotspots to Reach Adolescent Girls and Young Women Living with HIV: A Cross-sectional Study in Mombasa, Kenya”. In: *Journal of Acquired Immune Deficiency Syndromes* 84.5 (Aug. 2020), pp. 470–479.
- [56] Chido D. Chikwari, Stefanie Dringus, and Rashida A. Ferrand. “Barriers to, and emerging strategies for, HIV testing among adolescents in sub-Saharan Africa”. In: *Current Opinion in HIV and AIDS* 13.3 (May 2018), pp. 257–264.
- [57] Peter Ehrenkranz, Anna Grimsrud, and Miriam Rabkin. “Differentiated service delivery: Navigating the path to scale”. In: *Current Opinion in HIV and AIDS* 14.1 (Jan. 2019), pp. 60–65.
- [58] Katrina F. Ortblad et al. “The arc of HIV epidemics in sub-Saharan Africa: New challenges with concentrating epidemics in the era of 90–90–90”. In: *Current Opinion in HIV and AIDS* 14.5 (Sept. 2019), pp. 354–365.

- [59] Kelsey K Case, Gabriela B Gomez, and Timothy B Hallett. “The impact, cost and cost-effectiveness of oral pre-exposure prophylaxis in sub-Saharan Africa: a scoping review of modelling contributions and way forward”. In: *Journal of the International AIDS Society* 22.9 (Sept. 2019).
- [60] Jay G. Silverman. “Adolescent female sex workers: Invisibility, violence and HIV”. In: *Archives of Disease in Childhood* 96.5 (May 2011), pp. 478–481.
- [61] Rebecca F. Baggaley et al. “Heterosexual Anal Intercourse: A Neglected Risk Factor for HIV?” In: *American Journal of Reproductive Immunology* 69.SUPPL.1 (Feb. 2013), pp. 95–105.